In Silico Oncology: Quantification of the In Vivo Antitumor Efficacy of Cisplatin-Based Doublet Therapy in Non-Small Cell Lung Cancer (NSCLC) through a Multiscale Mechanistic Model

• Eleni Kolokotroni,

  Affiliation In Silico Oncology and In Silico Medicine Group, Institute of Communication and Computer Systems, National Technical University of Athens, Athens, Greece

  ⨯
• Dimitra Dionysiou,

  Affiliation In Silico Oncology and In Silico Medicine Group, Institute of Communication and Computer Systems, National Technical University of Athens, Athens, Greece

  ⨯
• Christian Veith,

  Affiliation Institute of Pathology, University of Saarland, Homburg (Saar), Germany

  ⨯
• Yoo-Jin Kim,

  Affiliation Institute of Pathology, University of Saarland, Homburg (Saar), Germany

  ⨯
• Jörg Sabczynski,

  Affiliation Philips Research, Hamburg, Germany

  ⨯
• Astrid Franz,

  Affiliation Philips Research, Hamburg, Germany

  ⨯
• Aleksandar Grgic,

  Affiliation Department of Nuclear Medicine, University of Saarland, Homburg (Saar), Germany

  ⨯
• Jan Palm,

  Affiliation Department of Radiotherapy and Radiation Oncology, University of Saarland, Homburg (Saar), Germany

  http://orcid.org/0000-0003-1122-1557

  ⨯
• Rainer M. Bohle,

  Affiliation Institute of Pathology, University of Saarland, Homburg (Saar), Germany

  ⨯
• Georgios Stamatakos

  * E-mail: gestam@central.ntua.gr

  Affiliation In Silico Oncology and In Silico Medicine Group, Institute of Communication and Computer Systems, National Technical University of Athens, Athens, Greece

  ⨯